SRPT Sarepta Therapeutics Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: SRPT
  4. Earnings
?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 28
Relative Valuation: Rel. Valuation: 72
Relative Profitability: Rel. Profitability: 54

EPS in 2026 (TTM): $0.6

Last Report Period Date: Mar 31, 2026

Based on the company's latest reports for March 2026, the current 12-month EPS is $0.6. Sarepta Therapeutics's earnings per share in 2025 was reported at -$7.13, marking a decline from $2.47 in 2024. In the quarterly report ending on Mar 31, 2026, SRPT's earnings per share amounted to $3.15.

SRPT earnings history

Historical annual and quarterly earnings per share (EPS) data for Sarepta Therapeutics
EPS (TTM)
$0.6
EPS Growth YoY (Quarterly)
168.5%
EPS (Quarterly)
$3.15
EPS Growth (Quarterly)
214.1%

Sarepta Therapeutics had an yealy earnings per share of -$7.13, showing a decline of 388.7% from $2.47 recorded in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was $3.15, showing a 168.5% increase compared to the same quarter last year. The trailing twelve months EPS for SRPT is $0.6 as of March 2026. Sarepta Therapeutics's full-year EPS for 2024 was $2.47, a 142.6% rise compared to the previous year.

SRPT earnings chart

SRPT EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
168.5%
EPS growth YoY
-388.7%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

In the past 12 months, Sarepta Therapeutics has recorded an earnings per share growth rate of 168.5% (YoY, quarterly).

SRPT Earnings Waterfall

Breakdown of revenue, profit and net income for Sarepta Therapeutics

SRPT Earnings vs Peers

What are the earnings of SRPT compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
GILD Gilead Sciences Inc 16.85 1,700% 23.2% 132.8%
SRPT Sarepta Therapeutics Inc 28.77 -388.7% N/A N/A
ALNY Alnylam Pharmaceuticals Inc 66.1 209.6% N/A N/A
NVAX Novavax Inc N/A 321.1% N/A N/A
PTCT Ptc Therapeutics Inc N/A 281.4% N/A N/A
BCRX Biocryst Pharmaceuticals Inc N/A 393% N/A N/A
INSM INSMED Inc N/A -15.3% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.